Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2=neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide

Human Gene Therapy

Volumn 21, Issue 2, 2010, Pages 157-170

  Liu, Xinjian ^a,b   Li, Jinjun ^a   Tian, Yuhua ^a   Xu, Ping ^a,b   Chen, Xiafang ^a   Xie, Kuangchen ^a   Qiu, Zhengjun ^a   Wang, Yufei ^a   Zhang, Dabing ^a   Wolf, Frank ^c   Li, Chuanyuan ^c   Huang, Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GENOMIC DNA; IMMUNOTOXIN; INTERLEUKIN 12;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; ETOPOSIDE; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTOXINS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; VIRUS REPLICATION;

ADENOVIRIDAE; MUS;

EID: 77249117857     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.083     Document Type: Article

References (42)

1. Azzariti, A., Porcelli, L., Gatti, G., Nicolin, A., and Paradiso, A. (2008). Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Bio-chem. Pharmacol. 75, 1035-1044.
2. Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L., and Finberg, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
3. Bergelson, J.M., Krithivas, A., Celi, L., Droguett, G., Horwitz, M.S., Wickham, T., Crowell, R.L., and Finberg, R.W. (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 72, 415-419.
4. Bruns, C.J., Solorzano, C.C., Harbison, M.T., Ozawa, S., Tsan, R., Fan, D., Abbruzzese, J., Traxler, P., Buchdunger, E., Radinsky, R., and Fidler, I.J. (2000). Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60, 2926-2935.
5. Cardenes, H.R., Chiorean, E.G., Dewitt, J., Schmidt, M., and Loehrer, P. (2006). Locally advanced pancreatic cancer: Current therapeutic approach. Oncologist 11, 612-623.
6. Cohen, C.J., Shieh, J.T., Pickles, R.J., Okegawa, T., Hsieh, J.T., and Bergelson, J.M. (2001). The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc. Natl. Acad. Sci. U.S.A. 98, 15191-15196.
7. Coyne, C.B., and Bergelson, J.M. (2005). CAR: A virus receptor within the tight junction. Adv. Drug Deliv. Rev. 57, 869-882.
8. Cross, D., and Burmester, J.K. (2006). Gene therapy for cancer treatment: Past, present and future. Clin. Med. Res. 4, 218-227.
9. Czito, B.G., Willett, C.G., Bendell, J.C., Morse, M.A., Tyler, D.S., Fernando, N.H., Mantyh, C.R., Blobe, G.C., Honeycutt, W., Yu, D., Clary, B.M., Pappas, T.N., Ludwig, K.A., and Hurwitz, H.I. (2006). Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J. Clin. Oncol. 24, 656-662.
10. v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6, 1520-1535.
11. Fleige, S., Walf, V., Huch, S., Prgomet, C., Sehm, J., and Pfaffl, M.W. (2006). Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative realtime RT-PCR. Biotechnol. Lett. 28, 1601-1613.
12. Furuuchi, K., Berezov, A., Kumagai, T., and Greene, M.I. (2007). Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. J. Immunol. 178, 1021-1029.
13. Guo, X., and Cui, Z. (2005). Current diagnosis and treatment of pancreatic cancer in China. Pancreas 31, 13-22.
14. Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249.
15. Honda, T., Saitoh, H., Masuko, M., Katagiri-Abe, T., Tominaga, K., Kozakai, I., Kobayashi, K., Kumanishi, T., Watanabe, Y.G., Odani, S., and Kuwano, R. (2000). The coxsackievirus-ade-novirus receptor protein as a cell adhesion molecule in the developing mouse brain. Brain Res. 77, 19-28.
16. Huang, Q., Zhang, X., Wang, H., Yan, B., Kirkpatrick, J., Dewhrist, M.W., and Li, C.Y. (2004). A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res. 10, 1439-1445.
17. Hussein, D., Estlin, E.J., Dive, C., and Makin, G.W. (2006). Chronic hypoxia promotes hypoxia-inducible factor-1a-dependent resistance to etoposide and vincristine in neuro-blastoma cells. Mol. Cancer Ther. 5, 2241-2250.
18. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. (2007). Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66.
19. Johnen, H., Lin, S., Kuffner, T., Brown, D.A., Tsai, V.W., Bauskin, A.R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., Hunter, M., Fairlie, W.D., Lee, N.J., Enriquez, R.F., Baldock, P.A., Corey, E., Apple, F.S., Murakami, M.M., Lin, E.J., Wang, C., During, M.J., Sainsbury, A., Herzog, H., and Breit, S.N. (2007). Tumor-induced anorexia and weight loss are mediated by the TGF-b superfamily cytokine MIC-1. Nat. Med. 13, 1333-1340.
20. Kim, M.A., Jung, E.J., Lee, H.S., Lee, H.E., Jeon, Y.K., Yang, H.K., and Kim, W.H. (2007). Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum. Pathol. 38, 1386-1393.
21. Koeppen, H.K., Wright, B.D., Burt, A.D., Quirke, P., McNicol, A.M., Dybdal, N.O., Sliwkowski, M.X., and Hillan, K.J. (2001). Overexpression of HER2=neu in solid tumours: An immuno-histochemical survey. Histopathology 38, 96-104.
22. Korn, W.M., Macal, M., Christian, C., Lacher, M.D., McMillan, A., Rauen, K.A., Warren, R.S., and Ferrell, L. (2006). Expression of the coxsackievirus and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther. 13, 792-797.
23. Lebedeva, I.V., Sarkar, D., Su, Z.Z., Gopalkrishnan, R.V., Athar, M., Randolph, A., Valerie, K., Dent, P., and Fisher, P.B. (2006). Molecular target-based therapy of pancreatic cancer. Cancer Res. 66, 2403-2413.
24. Lee, C.T., Park, K.H., Yanagisawa, K., Adachi, Y., Ohm, J.E., Nadaf, S., Dikov, M.M., Curiel, D.T., and Carbone, D.P. (2004). Combination therapy with conditionally replicating adenovi-rus and replication defective adenovirus. Cancer Res. 64, 6660-6665.
25. Lee, C.T., Lee, Y.J., Kwon, S.Y., Lee, J., Kim, K.I., Park, K.H., Kang, J.H., Yoo, C.G., Kim, Y.W., Han, S.K., Chung, J.K., Shim, Y.S., Curiel, D.T., and Carbone, D.P. (2006). In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovi-rus and adenovirus-p27. Cancer Res. 66, 372-377.
26. Li, D., Xie, K., Wolff, R., and Abbruzzese, J.L. (2004). Pancreatic cancer. Lancet 363, 1049-1057.
27. -DDCT method. Methods 25, 402-408.
28. Nagata, Y., Lan, K.H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., Klos, K.S., Li, P., Monia, B.P., Nguyen, N.T., Hortobagyi, G.N., Hung, M.C., and Yu, D. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127.
29. Park, J.O., Lopez, C.A., Gupta, V.K., Brown, C.K., Mauceri, H.J., Darga, T.E., Manan, A., Hellman, S., Posner, M.C., Kufe, D.W., and Weichselbaum, R.R. (2002). Transcriptional control of viral gene therapy by cisplatin. J. Clin. Invest. 110, 403-410.
30. Pino, M.S., Shrader, M., Baker, C.H., Cognetti, F., Xiong, H.Q., Abbruzzese, J.L., and McConkey, D.J. (2006). Transforming growth factor a expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res. 66, 3802-3812.
31. Pritchard, K.I., Shepherd, L.E., O'Malley, F.P., Andrulis, I.L., Tu, D., Bramwell, V.H., and Levine, M.N. (2006). HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354, 2103-2111.
32. Sato, N., Mizumoto, K., Kusumoto, M., Nishio, S., Maehara, N., Urashima, T., Ogawa, T., and Tanaka, M. (2000). Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide. Br. J. Cancer 82, 1819-1826.
33. Shieh, G.S., Shiau, A.L., Yo, Y.T., Lin, P.R., Chang, C.C., Tzai, T.S., and Wu, C.L. (2006). Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deami-nase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model. Cancer Res. 66, 9957-9966.
34. Siegel, P.M., and Massague, J. (2003). Cytostatic and apoptotic actions of TGF-b in homeostasis and cancer. Nat. Rev. Cancer 3, 807-821.
35. Solorzano, C.C., Baker, C.H., Tsan, R., Traxler, P., Cohen, P., Buchdunger, E., Killion, J.J., and Fidler, I.J. (2001). Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 7, 2563-2572.
36. Tomko, R.P., Xu, R., and Philipson, L. (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 94, 3352-3356.
37. Tsiambas, E., Karameris, A., Dervenis, C., Lazaris, A.C., Gianna-kou, N., Gerontopoulos, K., and Patsouris, E. (2006). HER2=neu expression and gene alterations in pancreatic ductal adenocar-cinoma: A comparative immunohistochemistry and chromo-genic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP 7, 283-294.
38. Tzeng, C.W., Frolov, A., Frolova, N., Jhala, N.C., Howard, J.H., Vickers, S.M., Buchsbaum, D.J., Heslin, M.J., and Arnoletti, J.P. (2007). EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J. Surg. Res. 143, 20-26.
39. Waddington, S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., Pink, R., Buckley, S.M., Greig, J.A., Denby, L., Custers, J., Morita, T., Francischetti, I.M., Monteiro, R.Q., Barouch, D.H., Van Rooijen, N., Napoli, C., Havenga, M.J., Nicklin, S.A., and Baker, A.H. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409.
40. Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., and Arteaga, C.L. (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132-4141.
41. Yarden, Y., and Sliwkowski, M.X. (2001). Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137.
42. Zalatnai, A. (2007). Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. Cancer Treat. Rev. 33, 289-298.